TY - JOUR
T1 - The clinical relevance of MOG antibody testing in cerebrospinal fluid
AU - Reynolds, Molly
AU - Tan, Irene
AU - Nguyen, Kristy
AU - Merheb, Vera
AU - Lee, Fiona X. Z.
AU - Trewin, Benjamin P.
AU - Lerch, Magdalena
AU - Shah, Snehal
AU - Wolfe, Nigel
AU - Buzzard, Katherine
AU - Lechner-Scott, Jeannette
AU - Fabis-Pedrini, Marzena J.
AU - Fok, Anthony
AU - John, Nevin
AU - Kneebone, Chris
AU - Yiannikas, Con
AU - Brown, David A.
AU - Kermode, Allan G.
AU - Reddel, Stephen
AU - Dale, Russell C.
AU - Brilot, Fabienne
AU - Ramanathan, Sudarshini
AU - the Australasian MOGAD Study Group
AU - Adam, Robert
AU - Andersen, Jane
AU - Andrews, Ian
AU - Antony, Jayne
AU - Aouad, Patrick
AU - Badve, Monica
AU - Barnett, Michael H.
AU - Barton, Joshua
AU - Beadnall, Heidi
AU - Blum, Stefan
AU - Boggild, Michael
AU - Broadley, Simon
AU - Burrow, Jim
AU - Butzkueven, Helmut
AU - Bye, Ann
AU - Cairns, Anita
AU - Calvert, Sophie
AU - Chan, Fiona
AU - Chelakkadan, Shabeed
AU - Chu, Melissa
AU - Clark, Damian R.
AU - Cotter, Isabella
AU - Dela Cruz, Fionna
AU - Field, Deborah
AU - Fraser, Clare L.
AU - Fung, Victor S. C.
AU - Garber, Justin
AU - Geara, Serge
AU - Gill, Deepak
AU - Gupta, Sachin
AU - Hardy, Todd A.
AU - Hawke, Simon
AU - Henderson, Andrew P. D.
AU - Jeyakumar, Niroshan
AU - Jones, Dean L.
AU - Jones, Hannah F.
AU - Kalincik, Tomas
AU - Kiernan, Matthew
AU - Kilpatrick, Trevor
AU - Kornberg, Andrew J.
AU - Lawlor, Mitchell
AU - Leventer, Richard J.
AU - Li, Vivien
AU - Ling, Simon
AU - Liyanage, Ganesha
AU - Lopez, Joseph A.
AU - Ma, Kit Kwan Margaret
AU - Malone, Stephen
AU - Marriot, Mark P.
AU - McCombe, Pamela
AU - McDougall, Alan
AU - Menezes, Manoj P.
AU - Miteff, Christina
AU - Monif, Mastura
AU - Musuwadi Subramanian, Gopinath
AU - Nguyen, Ai Lan
AU - O'Grady, Gina
AU - O'Neill, John
AU - Ouvrier, Robert
AU - Paine, Mark
AU - Parratt, John
AU - Pillai, Sekhar
AU - Prosser, Jane
AU - Qiu, Jessica
AU - Riminton, Sean D. S.
AU - Roos, Izanne
AU - Sandbach, Jennifer
AU - Scheffer, Ingrid E.
AU - Shah, Ubaid
AU - Shuey, Neil
AU - Sinclair, Adriane
AU - Siriratnam, Pakeeran
AU - Slee, Mark
AU - Spooner, Claire G.
AU - Sutton, Ian
AU - Swaminathan, Sanjay
AU - Tantsis, Esther
AU - Thomas, James
AU - Thomas, Terrence
AU - Thompson, Julia
AU - Troedson, Christopher
AU - Van der Walt, Anneke
AU - Vucic, Steve
AU - Wang, Justine
AU - Ware, Tyson
AU - Webster, Richard
AU - Lin, Ming Wei
AU - White, Owen
AU - Yeh, Wei
AU - Yiu, Eppie M.
AU - Zhong, Michael
N1 - Copyright the Author(s) 2024. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.
PY - 2024/9
Y1 - 2024/9
N2 - Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is diagnosed by serum MOG-immunoglobulin G (MOG-IgG) in association with typical demyelination. 111/1127 patients with paired CSF/serum samples were seropositive for MOG-IgG. Only 7/1016 (0.7%) seronegative patients had CSF-restricted MOG-IgG. While 3/7 patients had longitudinally extensive transverse myelitis, four had a confirmed alternate diagnosis (three multiple sclerosis, one CNS vasculitis). In a national referral setting, CSF-restricted MOG-IgG had a low sensitivity (2.63%, 95%CI 0.55–7.50%) and low positive predictive value (1.97%, 95%CI 0.45–8.13%). We strongly recommend serum as the preferred diagnostic biospecimen, and urge caution in the interpretation of CSF-restricted MOG-IgG in patients without clinico-radiological features consistent with MOGAD.
AB - Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is diagnosed by serum MOG-immunoglobulin G (MOG-IgG) in association with typical demyelination. 111/1127 patients with paired CSF/serum samples were seropositive for MOG-IgG. Only 7/1016 (0.7%) seronegative patients had CSF-restricted MOG-IgG. While 3/7 patients had longitudinally extensive transverse myelitis, four had a confirmed alternate diagnosis (three multiple sclerosis, one CNS vasculitis). In a national referral setting, CSF-restricted MOG-IgG had a low sensitivity (2.63%, 95%CI 0.55–7.50%) and low positive predictive value (1.97%, 95%CI 0.45–8.13%). We strongly recommend serum as the preferred diagnostic biospecimen, and urge caution in the interpretation of CSF-restricted MOG-IgG in patients without clinico-radiological features consistent with MOGAD.
UR - https://www.scopus.com/pages/publications/85200024428
U2 - 10.1002/acn3.52163
DO - 10.1002/acn3.52163
M3 - Article
C2 - 39073255
AN - SCOPUS:85200024428
SN - 2328-9503
VL - 11
SP - 2514
EP - 2519
JO - Annals of Clinical and Translational Neurology
JF - Annals of Clinical and Translational Neurology
IS - 9
ER -